Roche/Maxygen Early-Stage HCV/HBV Candidate Faces Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
MAXY-alpha has been put on clinical hold based on Phase I observations.
You may also be interested in...
Roche/Maxygen Halt Development Of Next-Generation Pegasys Candidate
End of Roche relationship has no financial impact on Maxygen, which plans an update on unpartnered Phase II neutropenia candidate MAXY-G34 for early 2008, firm tells “The Pink Sheet” DAILY.
Roche/Maxygen Halt Development Of Next-Generation Pegasys Candidate
End of Roche relationship has no financial impact on Maxygen, which plans an update on unpartnered Phase II neutropenia candidate MAXY-G34 for early 2008, firm tells “The Pink Sheet” DAILY.
Roche Backs Out Of Collaboration With Trimeris On Next-Generation Fusion Inhibitor
Major management shake-up includes departure of Trimeris CEO.